REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
REVLIMID Videos and Perspectives
The DRd Combination
Hear Dr. Davies, a multiple myeloma specialist at NYU Langone Health, talk about treating newly diagnosed MM patients ineligible for a stem cell transplant with REVLIMID + dex + dara (DRd).
Maintenance Therapy
Dr. Randolph, a hematologist/
oncologist at the Hollings Cancer Center, discusses data that supports his use of REVLIMID as maintenance therapy after a transplant.
Continuous Treatment
Dr. Landau, a hematologist/
oncologist at Orlando Health UF Health Cancer Center, shares how continuous therapy fits into his treatment approach for his patients with multiple myeloma, even when they have a complete response.
Mechanism of Action
Learn about the immunomodulatory, tumoricidal and antiangiogenic properties of lenalidomide.
Information about DRd does not appear in the REVLIMID full Prescribing Information.
Please see the daratumumab full Prescribing Information and Important Safety
Information at www.darzalex.com.
MAINTENANCE THERAPY
The only FDA-approved maintenance therapy post auto-HSCT.1

RENAL DOSING
REVLIMID can be used in all levels of renal function.1
Adjustments to the starting dose of REVLIMID are recommended to provide appropriate drug exposure in patients with renal impairment.1

#1 PRESCRIBED.
REVLIMID is the most prescribed NDMM therapy.3*
*Claims data 07/2017-06/2020. Source: IntrinsiQ Data © 2020, IntrinsiQ Specialty Solutions, Inc.

A single source for access support.
At Celgene Patient Support, we care about making sure your patients get the answers they need.

Customizable treatment calendar.
MM appointments and treatment schedules can get complicated. Help patients stay organized with this customizable calendar that you can email or print.
auto-HSCT, autologous hematopoietic stem cell transplantation; dex, dexamethasone; dara, daratumumab; NDMM, newly diagnosed multiple myeloma; NSCT, non-stem cell transplant.
References: 1. REVLIMID [package insert]. Summit, NJ: Celgene Corp; 2019. 2. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2019. 3. Data on file. Celgene Corp; 2020.